Insider Selling: Alkermes plc (NASDAQ:ALKS) Director Sells 10,000 Shares of Stock

Alkermes plc (NASDAQ:ALKSGet Rating) Director Shane Cooke sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, May 2nd. The stock was sold at an average price of $29.23, for a total value of $292,300.00. Following the transaction, the director now owns 90,478 shares in the company, valued at $2,644,671.94. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shane Cooke also recently made the following trade(s):

  • On Monday, April 25th, Shane Cooke sold 10,000 shares of Alkermes stock. The stock was sold at an average price of $27.88, for a total value of $278,800.00.
  • On Monday, April 18th, Shane Cooke sold 10,000 shares of Alkermes stock. The stock was sold at an average price of $28.88, for a total value of $288,800.00.
  • On Monday, April 11th, Shane Cooke sold 10,000 shares of Alkermes stock. The stock was sold at an average price of $29.26, for a total value of $292,600.00.
  • On Monday, April 4th, Shane Cooke sold 10,000 shares of Alkermes stock. The stock was sold at an average price of $28.18, for a total value of $281,800.00.

ALKS opened at $29.00 on Wednesday. The stock has a market cap of $4.74 billion, a PE ratio of -76.32 and a beta of 0.75. The company has a quick ratio of 1.86, a current ratio of 2.19 and a debt-to-equity ratio of 0.27. The business has a 50 day moving average of $26.97 and a 200-day moving average of $25.61. Alkermes plc has a 52 week low of $21.17 and a 52 week high of $33.00.

Alkermes (NASDAQ:ALKSGet Rating) last announced its quarterly earnings data on Wednesday, April 27th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.01 by $0.11. The business had revenue of $278.55 million during the quarter, compared to analysts’ expectations of $256.02 million. Alkermes had a positive return on equity of 3.87% and a negative net margin of 5.13%. The firm’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.01 earnings per share. Equities analysts anticipate that Alkermes plc will post -0.63 EPS for the current year.

Large investors have recently made changes to their positions in the business. Steward Partners Investment Advisory LLC raised its stake in Alkermes by 100.0% during the first quarter. Steward Partners Investment Advisory LLC now owns 1,000 shares of the company’s stock valued at $26,000 after buying an additional 500 shares during the last quarter. Credit Agricole S A purchased a new position in Alkermes during the fourth quarter valued at $35,000. UMB Bank N A MO purchased a new position in Alkermes during the fourth quarter valued at $47,000. SouthState Corp purchased a new position in shares of Alkermes in the third quarter worth $77,000. Finally, Altshuler Shaham Ltd raised its stake in shares of Alkermes by 130.9% in the third quarter. Altshuler Shaham Ltd now owns 4,069 shares of the company’s stock worth $126,000 after purchasing an additional 2,307 shares during the last quarter. Institutional investors and hedge funds own 98.93% of the company’s stock.

A number of brokerages have recently weighed in on ALKS. Mizuho lifted their price objective on Alkermes from $35.00 to $36.00 in a research report on Thursday, April 28th. Stifel Nicolaus lifted their price objective on Alkermes from $24.00 to $27.00 in a research report on Wednesday, April 27th. Citigroup lifted their price objective on Alkermes from $22.00 to $26.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 22nd. HC Wainwright lifted their price objective on Alkermes from $30.00 to $32.00 in a research report on Thursday, April 28th. Finally, SVB Leerink lifted their price objective on Alkermes from $24.00 to $25.00 and gave the stock a “market perform” rating in a research report on Thursday, April 21st. One analyst has rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Alkermes presently has an average rating of “Hold” and an average target price of $30.90.

Alkermes Company Profile (Get Rating)

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases.

Read More

Insider Buying and Selling by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.